Professional Marketing Briefs

Share this article:
Novo Nordisk was ranked tops by endocrinologists in an SDI survey. The company was mentioned by 62% of endocrinologists, up from 52% last year. Lilly came in second, mentioned by 53%, followed by Sanofi-Aventis. During the 12 months ending in April, Lilly reps made the most sales calls to endocrinologists, accounting for 12% of all calls to the specialists, followed by Novo Nordisk, which accounted for 10%, and the volume of calls made by each company increased over the previous 12 month period.

Eisai made a bet on obesity, signing a multi-million dollar deal with Arena Pharmaceuticals for the right to sell Arena's lorcaserin weight-loss pill, if approved. The deal includes a $50-million upfront, another $160 million based on development and approval milestones and a $1.16 billion, one-time payment that may follow based on annual sales.

GlaxoSmithKline laid off some 700 sales and marketing posts from its US commercial staff, along with related support personnel, reported the Wall Street Journal's Health Blog. While many of the jobs were eliminated, many other staffers have taken buyouts in recent months. GSK's last big round of pink slips was a 12% reduction in sales forces in 2008.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Is your marketing strategy stuck in 2005?

Is your marketing strategy stuck in 2005?

It is not enough to just have a killer black book or Rolodex. The market needs agile, swift marketing

Is guidance stifling social media?

Recent FDA draft guidance was meant to help companies create FDA-compliant tweets and handle third-party misinformation on the web. What other obstacles lie in the path of effective social media use?

FDA social media guides draw flak

FDA social media guides draw flak

Two FDA guidance documents on how health product manufacturers may participate in social media have drawn criticism from industry and consumer groups.